Mark Frydenberg

Prof. Mark Frydenberg


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2022 in Medical Journal of Australia
Verified
Journal Article
Open access
IWIsabella Sc Williams
Isabella Sc Williams
AMAoife McVey
Aoife McVey
SPSachin Perera
Sachin Perera
JOJonathan S O’bRien
Jonathan S O’bRien
LKLouise Kostos
Louise Kostos
MFMark Frydenberg
Mark Frydenberg
Early detection and management of prostate cancer has evolved over the past decade, with a focus now on harm minimisation and reducing overdiagnosis and overtreatment, given the proven improvements in survival from randomised controlled trials. Multiparametric magnetic resonance imaging (mpMRI) is now an important aspect of the diagnostic pathway in prostate cancer, improving the detection of clinically significant prostate cancer, enabling accurate localisation of appropriate sites to biopsy, and reducing unnecessary biopsies in most patients with normal magnetic resonance imaging scans. Biopsies are now performed transperineally, substantially reducing the risk of post‐procedure sepsis. Australian‐led research has shown that prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has superior accuracy in the staging of prostate cancer than conventional imaging (CT and whole‐body bone scan). Localised prostate cancer that is low risk (International Society for Urological Pathology [ISUP] grade 1, Gleason score 3 + 3 = 6; and ISUP grade group 2, Gleason score 3 + 4 = 7 with less than 10% pattern 4) can be offered active surveillance, reducing harms from overtreatment. Prostatectomy and definitive radiation remain the gold standard for localised intermediate and high risk disease. However, focal therapy is an emerging experimental treatment modality in Australia in carefully selected patients. The management of advanced prostate cancer treatment has evolved to now include several novel agents both in the metastatic hormone‐sensitive and castration‐resistant disease settings. Multimodal therapy with androgen deprivation therapy, additional systemic therapy and radiotherapy are often recommended. PSMA‐based radioligand therapy has emerged as a treatment option for metastatic castration‐resistant prostate cancer and is currently being evaluated in earlier disease states.

1 February 2020 in European Urology Oncology
Verified
Journal Article
Closed access
AKArveen A. Kalapara
Arveen A. Kalapara
JVJan F.M. Verbeek
Jan F.M. Verbeek
DNDaan Nieboer
Daan Nieboer
MFMichael Fahey
Michael Fahey
VGVincent Gnanapragasam
Vincent Gnanapragasam
SBSophie Bruinsma
Sophie Bruinsma

15 August 2024 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
Shadi A. EsfahaniShadi A. Esfahani
Shadi A. Esfahani
MMMichael J. Morris
Michael J. Morris
OSOliver Sartor
Oliver Sartor
MFMark Frydenberg
Mark Frydenberg
Stefano FantiStefano Fanti
Stefano Fanti
NVNeha Vapiwala
Neha Vapiwala
Purpose: Accurate diagnosis and staging of prostate cancer are crucial to improving patient care. Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography with computed tomography (PET/CT) imaging has demonstrated superiority for initial staging and restaging in patients with prostate cancer. Referring physicians and PET/CT readers must agree on a consistent communication method and application of information derived from this imaging modality. While several guidelines have been published, a single PSMA PET/CT reporting template has yet to be widely adopted. Based on the consensus from community and academic physicians, we developed a standardized PSMA PET/CT reporting template for radiologists and nuclear medicine physicians to report and relay key imaging findings to referring physicians. The aim was to improve the quality, clarity, and utility of imaging results reporting to facilitate patient management decisions. Methods: Based on community and expert consensus, we developed a standardized PSMA PET/CT reporting template to deliver key imaging findings to referring clinicians. Results: Core category components proposed include a summary of any prior treatment history; presence, location, and degree of PSMA radiopharmaceutical uptake in primary and/or metastatic tumor(s), lesions with no uptake, and incidentally found lesions with positive uptake on PET/CT. Conclusions: This article provides recommendations on best practices for standardized reporting of PSMA PET/CT imaging. The generated reporting template is a proposed supplement designed to educate and improve data communication between imaging experts and referring physicians.

1 April 2018 in European Urology
Verified
Journal Article
Closed access
MFMark Frydenberg
Mark Frydenberg
HWHenry H. Woo
Henry H. Woo


23 September 2014 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
MFMark Frydenberg
Mark Frydenberg